High Content Screening
Fluofarma has developed a High Content Screening (HCS) technology that improves the level of understanding of compounds and their effects, from the earliest stage of the discovery process onwards.
Base of HCS
High Content Screening is a powerful automated cell biology method that enables the functional analysis of several molecular events simultaneously in living cells. Key parameters to identify, select and characterize innovative compounds are measured by automated 96-well plate flow cytometry.
Breaking news
Scientific Publication
Fluofarma is glad to announce a new scientific publication in the journal Biochimica et Biophysica Acta - Molecular Cell Research.Read more [+]
IFSCC 2008
Fluofarma will be attending IFSCC 2008, in Barcelona, from October 6th to 9th.Read more [+]
INVITOX 2008
Fluofarma will be attending the INVITOX 2008 meeting, in Stockholm from September 25th to 28th.Read more [+]
EuroBio 2008
Fluofarma will be attending EuroBio 2008, in Paris from October 7th to 9th.Read more [+]
SMi's Cell-Based Assays 2008
Fluofarma will be attending SMi's Cell-Based Assays conference, in London from November 19th to 20th.Read more [+]
GDDI Forum 2009
Fluofarma will be attending Global Discovery & Development Innovation Forum 2009, in London, from March 2nd to 3rd.Read more [+]
FOCUS: Anticancer drugs profiling
Fluofarma has developed DCffer® method, a powerful approach to
compare and profile your anti-cancer drugs. Read
more [+]